MMP2 and Stroke: A synthetic MMP inhibitor (BB-1101) blocked the increase in brain MMP-2 levels, but it did not have any effect on stroke lesion size at 48 h after MCAO and had significant adverse effects on neurologic function in rats at 3 and 4 weeks after MCAO (Rosenberg et al., 1992, 1998; Yang et al., 2007).